Patients with neurological or psychiatric complications of COVID-19 have worse long-term functional outcomes: COVID-CNS-A multicentre case-control study.

Publication date: Jan 27, 2025

It is established that patients hospitalised with COVID-19 often have ongoing morbidity affecting activity of daily living (ADL), employment, and mental health. However, little is known about the relative outcomes in patients with COVID-19 neurological or psychiatric complications. We conducted a UK multicentre case-control study of patients hospitalised with COVID-19 (controls) and those who developed COVID-19 associated acute neurological or psychiatric complications (cases). Among the 651 patients, [362 (55%) cases and 289 (45%) controls], a higher proportion of cases had impairment in ADLs (199 [68. 9%] vs 101 [51. 8%], OR 2. 06, p

Open Access PDF

Concepts	Keywords
Daily	Adult
Hospitalised	Aged
Morbidity	Case-Control Studies
	COVID-19
	Employment
	Female
	Humans
	Male
	Mental Disorders
	Middle Aged
	Nervous System Diseases
	SARS-CoV-2
	United Kingdom

Semantics

Type	Source	Name
disease	MESH	complications
disease	MESH	COVID-19
disease	MESH	morbidity
disease	MESH	Long Covid
disease	MESH	depression
disease	MESH	anxiety
disease	MESH	hypertension
disease	MESH	Infection
disease	MESH	Zoonotic Infections
disease	MESH	Psychosis
drug	DRUGBANK	Coenzyme M
disease	MESH	Arthritis
disease	MESH	Inflammation
disease	MESH	syndromes
disease	MESH	anosmia
disease	MESH	ageusia
disease	MESH	dysgeusia
disease	MESH	cerebrovascular disease
disease	MESH	encephalopathy
disease	MESH	delirium
disease	MESH	acute disseminated encephalomyelitis
drug	DRUGBANK	Methionine
disease	MESH	psychiatric diagnosis
disease	MESH	uncertainty
disease	MESH	frailty
disease	MESH	multiple sclerosis
disease	MESH	dementia
disease	MESH	neurological disorders
disease	MESH	myelitis
disease	IDO	history
disease	MESH	anxiety disorder
disease	MESH	Amyotrophic lateral sclerosis
pathway	KEGG	Amyotrophic lateral sclerosis
disease	MESH	peripheral neuropathies
disease	MESH	seizures
disease	MESH	movement disorders
disease	MESH	retirement
drug	DRUGBANK	Isoxaflutole
drug	DRUGBANK	Oxygen
drug	DRUGBANK	Angiotensin II
drug	DRUGBANK	Dexamethasone
disease	MESH	functional status
disease	MESH	stroke
disease	MESH	encephalitis
disease	MESH	neurological manifestations
drug	DRUGBANK	Saquinavir
drug	DRUGBANK	Etoperidone
disease	IDO	blood
drug	DRUGBANK	Huperzine B
disease	MESH	viral infection
drug	DRUGBANK	L-Phenylalanine
disease	MESH	Respiratory Infections
pathway	REACTOME	Reproduction

Original Article

(Visited 2 times, 1 visits today)